ABSTRACT
Factor VIII (IX) inhibitors represent one of the most serious problems for the treatment of patients with hemophilia. The Blood Products Research Organization (Japan) has supported a study group for treatment of hemophiliacs with inhibitors. In 1995 the study group started a prospective matched control study of hemophiliacs with and without inhibitors and compared such factors as quality of life and economic cost. Each inhibitor patient was matched with a control patient in terms of age, type of hemophilia, and severity of hemophilia. A total of 136 patient-pairs were enrolled. Bleeding episodes were more frequent in the control group than in the inhibitor group. Days of hospitalization, days in wheelchairs, and the number of impaired joints were significantly higher for the inhibitor group. Number of blood-product infusions, days of bed rest at home, and days of brace use were the same for both groups. Blood-product expenditures were significantly higher for the inhibitor group than for the control group (yen 10,872,283/patient/year vs. yen 4,327,542/patient/year). Our study highlighted the higher cost of treatment and lower quality of life for hemophiliaes with Factor VII inhibitors.
Subject(s)
Factor IX/immunology , Factor VIII/immunology , Hemophilia A/immunology , Hemophilia A/therapy , Hemophilia B/immunology , Hemophilia B/therapy , Isoantibodies/blood , Quality of Life , Adult , Factor IX/antagonists & inhibitors , Factor VIII/antagonists & inhibitors , Hemophilia A/economics , Hemophilia B/economics , Humans , Prospective StudiesSubject(s)
HIV Core Protein p24/blood , HIV Seropositivity/diagnosis , Adult , Aged , Child , Humans , Immunoenzyme Techniques , Reagent Kits, DiagnosticABSTRACT
Seventy-five cases of head and neck cancer except of maxillary sinus, 27 cases of mesopharyngeal cancer, 6 cases of oral cancer, 9 cases of thyroid cancer and 9 cases of the other cancer, were treated with this multi-disciplinary treatment and the results were evaluated in this series. An intraarterial infusion drug, 5-FU, was used mainly through the superficial temporal artery. The five year survival rate was 46.1% in mesopharyngeal cancer, 34.4% in oral cancer and 33.3% in thyroid cancer. The results were relatively satisfactory despite the advanced stage of the cancer. Intraarterial chemotherapy has been a common treatment for maxillary cancer but the indication of this treatment should be developed in advanced head and neck cancer with radiotherapy or surgical treatment as a part of multi-disciplinary treatment.
